Page last updated: 2024-12-08
3-hydroxyterphenyllin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-hydroxyterphenyllin: metabolite of Aspergillus candidus; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3-hydroxyterphenyllin : A para-terphenyl that is the 3-hydroxy derivative of terphenyllin. It has been isolated from Aspergillus taichungensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 191796 |
| CHEMBL ID | 1795465 |
| CHEBI ID | 67536 |
| MeSH ID | M0074510 |
Synonyms (27)
| Synonym |
|---|
| nsc299113 |
| 3-hydroxyterphenyllin |
| 66163-76-6 |
| terphenyllin, hydroxy |
| nsc-299113 |
| hydroxyterphenyllin |
| [1,1':4',1''-terphenyl]-2',3,4,4''-tetrol, 3',6'-dimethoxy- |
| 4-[2-hydroxy-4-(4-hydroxyphenyl)-3,6-dimethoxy-phenyl]benzene-1,2-diol |
| 3',6'-dimethoxy-(1,1':4',1''-terphenyl)-2',3,4,4''-tetrol |
| 4-[2-hydroxy-4-(4-hydroxyphenyl)-3,6-dimethoxyphenyl]benzene-1,2-diol |
| chebi:67536 , |
| CHEMBL1795465 , |
| 3',6'-dimethoxy-1,1':4',1''-terphenyl-2',3,4,4''-tetrol |
| vez2nx1645 , |
| unii-vez2nx1645 |
| nsc 299113 |
| (1,1':4',1''-terphenyl)-2',3,4,4''-tetrol, 3',6'-dimethoxy- |
| [1,1':4',1''-terphenyl]-2',3,4,4''-tetrol,3',6'-dimethoxy- |
| AKOS030213164 |
| DTXSID70216353 |
| Q27136005 |
| 3',6'-dimethoxy-[1,1':4',1''-terphenyl]-2',3,4,4''-tetrol |
| bdbm50457917 |
| BS-1309 |
| HY-N10268 |
| PD069568 |
| CS-0371972 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| para-terphenyl | A ring assembly based on a 1,4-diphenylbenzene skeleton and its substituted derivatives thereof. |
| catechols | Any compound containing an o-diphenol component. |
| dimethoxybenzene | Any methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (4)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | IC50 (µMol) | 11.3000 | 0.0400 | 3.4652 | 9.0000 | AID1381559 |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | IC50 (µMol) | 11.3000 | 0.0600 | 2.2889 | 7.8000 | AID1381559 |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | IC50 (µMol) | 11.3000 | 0.0490 | 2.7294 | 7.8000 | AID1381559 |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | IC50 (µMol) | 11.3000 | 0.5400 | 4.0244 | 7.8000 | AID1381559 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (23)
Molecular Functions (10)
Ceullar Components (14)
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1381559 | Inhibition of human alpha-glucosidase expressed in Saccharomyces cerevisiae using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 15 mins | |||
| AID603560 | Cytotoxicity against mouse P388 cells by MTT assay | 2011 | Journal of natural products, May-27, Volume: 74, Issue:5 | Prenylated Polyhydroxy-p-terphenyls from Aspergillus taichungensis ZHN-7-07. |
| AID1381571 | Cytotoxicity against human HepG2 cells at 10 uM by SRB assay | |||
| AID1381584 | Cytotoxicity against human Chang cells at 10 uM by SRB assay | |||
| AID603561 | Cytotoxicity against human A549 cells by SRB assay | 2011 | Journal of natural products, May-27, Volume: 74, Issue:5 | Prenylated Polyhydroxy-p-terphenyls from Aspergillus taichungensis ZHN-7-07. |
| AID646596 | Inhibition of viral neuraminidase after 20 mins by fluorescence assay | 2012 | Journal of natural products, Jan-27, Volume: 75, Issue:1 | p-Terphenyl and diterpenoid metabolites from endophytic Aspergillus sp. YXf3. |
| AID1381569 | Cytotoxicity against human A549 cells at 10 uM by SRB assay | |||
| AID1381564 | Cytotoxicity against human MDA-MB-435 cells | |||
| AID1381570 | Cytotoxicity against human HeLa cells at 10 uM by SRB assay | |||
| AID603559 | Cytotoxicity against human HL60 cells by MTT assay | 2011 | Journal of natural products, May-27, Volume: 74, Issue:5 | Prenylated Polyhydroxy-p-terphenyls from Aspergillus taichungensis ZHN-7-07. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||